News Releases

– 94% of attacks required only one dose to achieve primary endpoint - – Further analyses demonstrate efficacy across all levels of attack severity - – Additional safety data reinforces flexibility of dosing - CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb.

– Provides entry to UK Innovative Licensing and Access Pathway (ILAP), which aims to accelerate time to market and facilitate patient access to innovative medicines – – Late-breaking sebetralstat phase 3 data to be presented at the upcoming 2024 American Academy of Allergy , Asthma & Immunology

– Late-breaking phase 3 data for KONFIDENT trial on Sunday, February 25, 2024   – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 16, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 15, 2024-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) today announced the pricing of its underwritten public offering of (i) 7,016,312 shares of its common stock at a price to the public of $15.25 per share and (ii)

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 14, 2024-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) announced today that it intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of common stock in lieu of KalVista common

– Sebetralstat 300 mg achieved beginning of symptom relief in 1.6 hours – – Safety profile comparable to placebo – – On track for submission of new drug application to U.S. FDA in the first half of 2024 – – Conference call to discuss trial results today at 8:30 a.m. ET – CAMBRIDGE, Mass.

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 2, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 42,000 shares of